Table of Contents

company-logo

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage. The company also develops TCR Bispecifics products, including IMA401, which is in Phase 1b clinical trial; and IMA402 and IMA403, which are in preclinical stages. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.

immatics biotechnologies Dividend Announcement

• immatics biotechnologies does not currently offer dividends, we're keeping a close eye on its growth potential and financial developments.
• Stay tuned for updates on immatics biotechnologies dividend policy and future announcements. In the meantime, explore other dividend-yielding opportunities on our website.

immatics biotechnologies Dividend History

immatics biotechnologies Dividend Yield

immatics biotechnologies current trailing twelve-month (TTM) dividend yield is -%. Interested in purchasing immatics biotechnologies stock? Use our calculator to estimate your expected dividend yield:

immatics biotechnologies Financial Ratios

P/E ratio-11.84
PEG ratio0.13
P/B ratio2.25
ROE-23.40%
Payout ratio0.00%
Current ratio3.74
Quick ratio3.74
Cash Ratio1.06

immatics biotechnologies Dividend FAQ

Does immatics biotechnologies stock pay dividends?
immatics biotechnologies does not currently pay dividends to its shareholders.
Has immatics biotechnologies ever paid a dividend?
No, immatics biotechnologies has no a history of paying dividends to its shareholders. immatics biotechnologies is not known for its dividend payments.
Why doesn't immatics biotechnologies pay dividends?
There are several potential reasons why immatics biotechnologies would choose not to pay dividends to their shareholders:

1. Growth opportunities: Companies, especially in fast-growing industries like technology, reinvest earnings into expansion, R&D, or acquisitions to fuel future growth and increase company value.

2. Tax implications: Not paying dividends can reduce the tax burden on shareholders, who may prefer to defer taxes until selling shares and realizing capital gains.

3. Investor preferences: Some investors prefer companies to reinvest profits for higher long-term returns, particularly those seeking capital appreciation over income.

4. Capital allocation priorities: Companies may allocate cash to pay down debt, fund share buybacks, or invest in projects with higher returns than dividends.

5. Market expectations: In certain sectors, like technology, reinvesting profits for growth and innovation is often prioritized over distributing dividends to shareholders.
Will immatics biotechnologies ever pay a dividend?
The decision for a company to pay dividends depends on various factors including its financial performance, growth prospects, capital allocation priorities, and shareholder preferences. While immatics biotechnologies has not paid dividends historically and has instead focused on reinvesting its earnings for growth, it's ultimately up to the company's management and board of directors to decide whether to initiate a dividend policy in the future.
Is immatics biotechnologies a dividend aristocrat?
immatics biotechnologies is not considered a Dividend Aristocrat. The term "Dividend Aristocrat" is typically used to describe a company in the S&P 500 index that has increased its dividend payouts for at least 25 consecutive years.
Is immatics biotechnologies a dividend king?
immatics biotechnologies is not classified as a "Dividend King". A Dividend King is a company that has managed to increase its dividend payouts for 50 consecutive years or more, which is an even more selective group than the Dividend Aristocrats.
Is immatics biotechnologies a dividend stock?
No, immatics biotechnologies is not considered a dividend stock. A dividend stock is a stock of a company that regularly pays out dividends to its shareholders.
How to buy immatics biotechnologies stocks?
To buy immatics biotechnologies you need a brokerage account. Open an account with a reputable brokerage firm that offers access to the stock market. Consider factors such as fees and account minimums.

Place an order: Use the brokerage's trading platform to place an order to buy immatics biotechnologies stock.

Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.